Double Eleven is coming soon.
Are everyone buying and buying?
At this time there is news of the "national team" from
!
November 5,
heart stents in the field of high-value medical consumables
due to the large clinical use and high price
became the first batch of national centralized procurement of consumables
involved 8 domestic and foreign manufacturers, 10 varieties The median price of
is only about 700 yuan! The average price of
dropped from 13,000 yuan to about 700 yuan.
The country organized the first centralized procurement of high-value medical consumables for coronary stents, and the proposed selection result was produced in Tianjin on November 5. Through competition, 10 products to be selected were produced. After this centralized procurement, the price of the bracket dropped from an average price of about 13,000 yuan to about 700 yuan for . Compared with 2019, the average price of the same products of the same company has been reduced by 93%, the average price of domestic products has been reduced by 92%, and the average price of imported products has been reduced by 95%. Based on the intended purchase volume, expects to save 10.9 billion yuan. expects that patients across the country will use the selected products after the national centralized procurement price reduction in January 2021. The demand for
is increasing, but the price of
remains high? drop! The
heart stent, also known as the coronary stent, is a consumable for percutaneous coronary intervention (PCI) and is the most effective means to reduce patient deaths. According to the relevant notice from the Shaanxi Provincial Medical Security Bureau, all public and military medical institutions in Xi'an that use more than 500 coronary stents in 2019 should participate in the procurement data reporting; in 2019, all public and military medical institutions that use more than 500 coronary stents Military medical institutions and medical insurance designated social medical institutions may participate in the procurement data reporting voluntarily.
The conditions for "full bidding" are ripe.
"China Cardiovascular Health and Disease Report 2019" shows that the current number of cardiovascular patients in my country reaches 330 million; from 2009 to 2019, the number of coronary heart disease (PCI) operations in China has increased from 230,000 cases have grown to more than 1 million cases, with an annual growth rate of 10%-20%.
1990-2017 China’s urban and rural residents’ cardiovascular mortality rate changes
based on the use of approximately 1.5 stents per surgical stent, my country uses 1.5 million cardiac stents a year. According to the National Medical Insurance Administration, China's medical consumables market is 320 billion yuan, of which high-value medical consumables 150 billion yuan. The total cost of coronary stents is about 15 billion yuan, and accounts for one-tenth of the total cost of high-value medical consumables in the country, .
is suitable for the country's first collection of high-value medical consumables in the field of heart stents due to the large clinical usage and sufficient competition, and the conditions for "full bidding" are ripe.
Consumables prices are inflated and price cuts are imperative
◆ Before the collection of , the prices of domestic products in the world were high:
found through the international price comparison of coronary stents that before the collection, the price of domestic heart stents was international On the high side.
domestic brand price 7500-18500 yuan, median 14000 yuan, imported brand price 11400-23300 yuan;
same generation stent price Brazil lowest 2183 yuan;
American patients pay 6403-18507 yuan;
French retail price 6881 yuan;
Japanese medical insurance pays 7693-18747 yuan (all equivalent to 2020 RMB exchange rate);
In March 2020, the Indian government stipulated that the ceiling price of drug-eluting stents was adjusted to 756 yuan.
◆ patients are expensive:
high-value medical consumables pricesInsufficient height and excessive use are the main reasons why the masses report the problem of "expensive medical care". solves the problem of expensive medical treatment, and medical equipment cannot be ignored.
Take Changxing County, Zhejiang Province as an example. In 2019, People's Hospital and Hospital of Traditional Chinese Medicine carried out more than 400 cases of coronary stent implantation. Due to the small number of uses, the price cannot be exchanged for quantity, which ultimately resulted in a tripartite passive situation where the hospital's operating costs were high, the medical insurance fund was under pressure, and patients could not afford it.
In May 2019, the eighth meeting of the Central Deep Reform Commission reviewed and approved the "Reform Plan for Governance of High-Value Medical Consumables", which required the exploration of the classified and centralized procurement of high-value medical consumables in accordance with the principles of quantity procurement, quantity price linkage, and promotion of market competition.
Jiangsu’s “first mover” pilot price has been greatly reduced
In order to steadily promote the reform of high-value consumables, in 2019, under the unified deployment of the country, Jiangsu Province took the lead in the first trial, and took the lead in the country to conduct provincial-level coronary stent recruitment work. "Quantity" was exchanged for "True Price", and the selected varieties fell by an average of 51%.
After the recruitment of Jiangsu Province, the price of the bracket was compressed between 2850 yuan and 8666 yuan. The selected varieties are consistent with the current mainstream varieties in clinical use and can better meet clinical needs. How to determine the selected product of
?
is ranked by price, and the quantity is first.
is ranked according to the order of the declared price of the product, with the lowest declared price being the first place, the second lowest being the second place, and so on. The top 10 products ranked first. When the price is the same, it will be ranked according to two major rules:
◆ Products with large sales volume in 2019 will be given priority (based on the historical procurement data submitted by each province)
◆ Enterprises that have obtained the first registration certificate from the National Medical Products Administration before the time Priority (subject to the date of first approval by the National Medical Products Administration)
product shortlisted conditions
shortlisted products that meet one of the following conditions will be eligible for the proposed selection:
◆ where the declared price is less than 1.8 times the minimum product declaration price;
◆ the declared price ＞1.8 times the minimum product declared price, but less than 2850 yuan. The proposed ranking is the same as the product ranking.
price reduction does not degrade quality low-cost heart stent "rest assured" use! After the news of
was sent, many netizens said:
Huimin! Good news for patients↓
and some netizens have questions↓
The price is so low, do patients dare to use it?
response:
Before the centralized recruitment, the relevant departments of Tianjin intensively investigated the Medical Device Quality Supervision and Inspection Center to find out the testing capabilities and ensure that the quality of the selected products can be traced to . Ensure that each product is safe and effective when applied to patients.
limits the material of the stent, will it limit the doctor's clinical choice?
response: and
heart stents from the same manufacturer and different brands can replace in 70% to 80% of clinical use. There are only a few irreplaceable cases, mainly due to the special specifications of the diameter and length of the stent. At present, the specifications of mainstream brands are relatively complete, and they can meet about 80% of the common clinical conditions. The national centralized procurement of
heart stents is not
only let the price "one drop" ,
, but aims to establish a new mechanism ,
work together to optimize the pharmaceutical market business environment. The
national collection of heart stents,
has built a "bridge" between medical consumption manufacturers and patients
,
will become another dazzling symbol of
on the road to deepening medical reform.
is such a domineering operation, you can do more!
◆ source| The Central Committee of the Communist Youth League, CCTV News Client, Popular Science China, Xi'an released
Edit | Land Tian
z67-
-
-
-
-
-
-
-
-
-